Antibody-Drug Conjugate Manufacturing: Clinical through Commercial ADC CDMO Services

We support the robust scaling of ADC clinical through to commercial manufacturing. We are dedicated to delivering excellence in quality, specializing in small molecule intermediates, including high-potency chemistry, payloads, linkers, and payload-linker chemical intermediates, as well as bioconjugation.

Our ADC and commercial bioconjugate manufacturing and process development facilities use unified, advanced technologies, ensuring efficient scale-up and minimizing risk for your commercial ADC program.

We ensure seamless ADC technology transfer and strict adherence to all product quality requirements.

Our scientific team have multiple decades of experience in the field of ADC production. We have robust and refined processes that have proven to accelerate customers programs and move ADCs forwards into clinical and commercial manufacturing.

We understand that ADC manufacturing is a complex multistep process which can be divided into three stages:

• cGMP production of the antibody
• cGMP synthesis of the drug-linker complex
• Conjugation to form an ADC

The conjugated antibodies then undergo extensive purification to remove therapeutic impurities. These are finished as ADC products upon the completion of fill-finishing.